BIOMAT Database Logo BIOMAT Database Logo

Type I collagen metabolites as tumor markers in patients with lung carcinoma. 1999

T Kobayashi, and E C Gabazza, and O Taguchi, and J Risteli, and L Risteli, and H Kobayashi, and H Yasui, and H Yuda, and T Sakai, and M Kaneda, and Y Adachi
Third Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan.

BACKGROUND Components of the extracellular matrix play a fundamental role in the process of tumor invasion. The objective of this study was to evaluate the value of Type I collagen metabolites as tumor markers in patients with lung carcinoma. METHODS In this study, the serum concentrations of the cross-linked carboxyterminal telopeptide of Type I collagen (ICTP) and the aminoterminal propeptide of Type I collagen (PINP) were measured in 59 consecutive patients with lung carcinoma. The blood concentrations of neuron-specific enolase (NSE), carcinoembryogenic antigen (CEA), sialyl Le-1 antigen (SLX), squamous cell carcinoma antigen (SCC), and D-dimer were also evaluated. Data obtained on 18 age-matched healthy subjects and 12 age-matched patients with benign lung disease were available for comparison. RESULTS The serum concentrations of PINP were significantly higher in patients with lung carcinoma than in age-matched controls. Prechemotherapy values of PINP and ICTP were significantly increased in patients who did not respond to chemotherapy compared with those who did respond. PINP and ICTP were significantly correlated with clinical stage, extent of bone metastasis, survival time, and D-dimer. PINP was also significantly correlated with tumor size. ICTP was significantly correlated with CEA, SLX, SCC, and NSE. PINP also tended to correlate with these tumor-associated glycoproteins. PINP had a better receiver operating characteristic curve than ICTP. The specificity of PINP (79%) for the diagnosis of bone metastasis was superior to that of ICTP (58%). CONCLUSIONS The results of this study showed that, in addition to the important information that ICTP and PINP provide about the tumor cell-extracellular matrix interaction, they appear to be of great value as adjunct tools for the diagnosis of bone metastasis and as markers of the clinical response to therapy, clinical progression, and prognosis in lung carcinoma patients. However, more studies must be conducted to evaluate further the utility of these markers before their application in clinical practice.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D005260 Female Females

Related Publications

T Kobayashi, and E C Gabazza, and O Taguchi, and J Risteli, and L Risteli, and H Kobayashi, and H Yasui, and H Yuda, and T Sakai, and M Kaneda, and Y Adachi
Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
November 1997, Cancer,
T Kobayashi, and E C Gabazza, and O Taguchi, and J Risteli, and L Risteli, and H Kobayashi, and H Yasui, and H Yuda, and T Sakai, and M Kaneda, and Y Adachi
Type I and type III collagen metabolites in adult osteosarcoma patients.
January 1996, British journal of cancer,
T Kobayashi, and E C Gabazza, and O Taguchi, and J Risteli, and L Risteli, and H Kobayashi, and H Yasui, and H Yuda, and T Sakai, and M Kaneda, and Y Adachi
Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
April 1994, The Journal of urology,
T Kobayashi, and E C Gabazza, and O Taguchi, and J Risteli, and L Risteli, and H Kobayashi, and H Yasui, and H Yuda, and T Sakai, and M Kaneda, and Y Adachi
Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis.
August 2019, Scientific reports,
T Kobayashi, and E C Gabazza, and O Taguchi, and J Risteli, and L Risteli, and H Kobayashi, and H Yasui, and H Yuda, and T Sakai, and M Kaneda, and Y Adachi
Serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma.
February 2002, Cancer,
T Kobayashi, and E C Gabazza, and O Taguchi, and J Risteli, and L Risteli, and H Kobayashi, and H Yasui, and H Yuda, and T Sakai, and M Kaneda, and Y Adachi
Tumor markers in patients with lung cancer.
April 1986, Chest,
T Kobayashi, and E C Gabazza, and O Taguchi, and J Risteli, and L Risteli, and H Kobayashi, and H Yasui, and H Yuda, and T Sakai, and M Kaneda, and Y Adachi
Peptide hormones as tumor markers in lung cancer patients.
January 1985, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
T Kobayashi, and E C Gabazza, and O Taguchi, and J Risteli, and L Risteli, and H Kobayashi, and H Yasui, and H Yuda, and T Sakai, and M Kaneda, and Y Adachi
Stimulated type I collagen turnover in patients with giant cell tumor of bone.
July 2003, Calcified tissue international,
T Kobayashi, and E C Gabazza, and O Taguchi, and J Risteli, and L Risteli, and H Kobayashi, and H Yasui, and H Yuda, and T Sakai, and M Kaneda, and Y Adachi
Publisher Correction: Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis.
August 2020, Scientific reports,
T Kobayashi, and E C Gabazza, and O Taguchi, and J Risteli, and L Risteli, and H Kobayashi, and H Yasui, and H Yuda, and T Sakai, and M Kaneda, and Y Adachi
Tumor markers in patients with pancreatic carcinoma.
July 1996, Cancer,
Copied contents to your clipboard!